SkinBioTherapeutics files new patent application
Manchester, UK - 14 May 2018 - SkinBioTherapeutics plc (AIM: SBTX, the "Company"), a life science company focused on skin health, announces a new patent filing.
The patent application is to cover the use of SkinBiotix for increasing filaggrin levels in skin.
Filaggrin is a protein which is vital to the formation of the outermost protective layer of skin. If filaggrin is absent, skin tends to become dry and irritated. It has been shown that those with severe forms of eczema can have half the level of filaggrin as a healthy individual. Work performed at the Company's laboratories has demonstrated that SkinBiotix can significantly increase the amount of filaggrin in human skin models.
This is the second successful test of the Company's technology, following earlier proof that SkinBiotix increases the 'tight junction' which exists in the inner layer of skin. The observation that the technology can improve both the surface and inner layers of skin suggests that SkinBiotix will be therapeutically useful in a range of conditions, such as eczema.
Dr Cath O'Neill, CEO of SkinBioTherapeutics, commented:
"SkinBiotix is continuing to prove its uniqueness as a platform via scientific testing. Following the successful work in skin models on fillagrin production, we are looking to increase the value and scope of our intellectual property with the filing of this patent."
"This is a continuation of our strategy to create an IP portfolio that allows us to robustly protect what we believe is a technology of significant commercial value in key global dermatalogical markets."14th May, 2018